Horizon snaps up rare disease drugs, pipeline, in $800M Raptor buyout
Horizon Pharma has bagged Raptor Pharmaceuticals $RPTP and a pair of rare disease drugs on the market — along with a multi-drug pipeline — in an $800 million cash deal. Horizon is paying $9 a share for Raptor, which also has been pursuing a troubled development path for a new drug for Huntington’s drug, now in a pivotal trial.
Horizon $HZNP is looking for some quick returns on Raptor’s two approved drugs, Procysbi and Quinsair, used to treat a rare metabolic disorder called nephropathic cystinosis and chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Procysbi has U.S. and European approvals, while Quinsair is OK’s in Europe and Canada.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.